Castle Biosciences, Inc. - Common stock (NQ:CSTL)

33.36 -3.29 (-8.98%)

Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

7 Analysts Have This to Say About Castle Biosciences ↗

June 05, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 05, 2023

Via Benzinga

Dow Drops Triple Digits; S&P 500, Nasdaq Extend Highs ↗

June 05, 2023

Via Talk Markets

Stocks That Hit 52-Week Lows On Monday ↗

June 05, 2023

Monday's session saw 41 companies set new 52-week lows.

Via Benzinga

Why Shares of Castle Biosciences Slumped This Week ↗

June 02, 2023

Investors were unimpressed by the company's study regarding its IDgenetix test.

Via The Motley Fool

Looking Into Castle Biosciences's Return On Capital Employed ↗

May 11, 2023

Via Benzinga

Analyst Expectations for Castle Biosciences's Future ↗

May 04, 2023

Via Benzinga

Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 05, 2023

Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding.

Via Benzinga

Nasdaq Rises 70 Points; ISM Services PMI Drops In May ↗

June 05, 2023

U.S. stocks traded mixed midway through trading, with Nasdaq Composite gaining around 70 points on Monday. The Dow traded down 0.21% to 33,691.13 while the NASDAQ rose 0.54% to 13,312.65. The S&P 500,...

Via Benzinga

EPAM Systems, Amyris, Blueprint Medicines And Other Big Stocks Moving Lower On Monday ↗

June 05, 2023

U.S. stocks traded mixed, with the Dow Jones dropping around 100 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

US Stocks Mixed; SAIC Posts Upbeat Results ↗

June 05, 2023

U.S. stocks traded mixed this morning, with Dow Jones dropping around 20 points on Monday. Following the market opening Monday, the Dow traded down 0.06% to 33,740.98 while the NASDAQ rose 0.08% to...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 05, 2023

Via Benzinga

Framework Incorporating DecisionDx®-SCC Test Results into Clinical Decision-Making for Patients with High-Risk Cutaneous Squamous Cell Carcinoma Published in Clinical, Cosmetic and Investigational Dermatology

June 05, 2023

From Castle Biosciences Inc.

Via Business Wire

Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting

June 03, 2023

From Castle Biosciences Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

June 01, 2023

Via Benzinga

IDgenetix® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder

May 31, 2023

From Castle Biosciences Inc.

Via Business Wire

Why Victoria's Secret Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 01, 2023

Gainers Reunion Neuroscience Inc. (NASDAQ: REUN) gained 95% to $1.33 after the company announced a $13.1 million take-private transaction with MPM BioImpact.

Via Benzinga

Castle Biosciences Celebrates Skin Cancer Awareness Month

May 30, 2023

From Castle Biosciences Inc.

Via Business Wire

Castle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as “Posters of Distinction” by the American Gastroenterological Association (AGA) Institute Council

May 26, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Opens New State-of-the-Art Laboratory in Pittsburgh

May 22, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation

May 15, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Reports First Quarter 2023 Results

May 03, 2023

From Castle Biosciences, Inc.

Via Business Wire

Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance Imaging Studies

May 03, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Collaborates with IMPACT Melanoma to Provide Free Sunscreen to Cyclists Participating in the Bike MS: Texas MS 150 2023 Cycling Event

April 28, 2023

From Castle Biosciences, Inc.

Via Business Wire

DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients

April 25, 2023

From Castle Biosciences, Inc.

Via Business Wire

TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett’s Esophagus Patients with Low-Grade Dysplasia

April 20, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3

April 19, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 12, 2023

From Castle Biosciences, Inc.

Via Business Wire

7 Value Stocks to Buy for Long-Term Growth ↗

March 26, 2023

If you have the patience to ride out some choppy weather, these value stocks to buy may offer significant upside later.

Via InvestorPlace

Late-Breaking Data Presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx®-SCC in Predicting Metastatic Risk Over Traditional Staging Systems in Independent, Multi-Center Cohort Study

March 18, 2023

From Castle Biosciences, Inc.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.